
Opinion|Videos|March 25, 2025
Navigating Cost Considerations in Treatment Selection of mCRC Agents
Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.
Advertisement
Video content above is prompted by the following:
- What are the key payer-related challenges (eg, step edits, prior authorizations) that impact access to third-line therapies for patients with mCRC?
- How do payer requirements influence treatment sequencing and decision-making in the third-line setting?
- How do the costs associated with adverse events across the different third-line treatments (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab) influence treatment selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
3
How Clinician-Led Partnerships Strengthen Post-Acute Care
4
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
5